Commentary | Published:

The 2010 scientific strategic plan of the Global HIV Vaccine Enterprise

Nature Medicine volume 16, pages 981989 (2010) | Download Citation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    UNAIDS & World Health Organization. AIDS Epidemic Update: November 2009. (UNAIDS, Geneva, 2009).

  2. 2.

    World Health Organization, UNAIDS & UNICEF. Towards Universal Access: Scaling up priority HIV/AIDS interventions in the health sector. (World Health Organization, Geneva, 2009).

  3. 3.

    & Nature 464, 224–231 (2010).

  4. 4.

    et al. N. Engl. J. Med. 361, 2209–2220 (2009).

  5. 5.

    Nature 464, 217–223 (2010).

  6. 6.

    , , , & Nat. Rev. Immunol. 10, 11–23 (2010).

  7. 7.

    et al. Proc. Natl. Acad. Sci. USA 105, 7552–7557 (2008).

  8. 8.

    & Curr. Opin. HIV AIDS 4, 352–357 (2009).

  9. 9.

    et al. Nat. Med. 13, 100–106 (2007).

  10. 10.

    et al. Nature 465, 350–354 (2010).

  11. 11.

    et al. AIDS 24, 1095–1105 (2010).

  12. 12.

    et al. Nat. Med. 15, 293–299 (2009).

  13. 13.

    et al. Science 326, 285–289 (2009).

  14. 14.

    et al. Science 329, 856–861 (2010).

  15. 15.

    et al. PLoS ONE 5, e8805 (2010).

  16. 16.

    et al. Nature 449, 101–104 (2007).

  17. 17.

    et al. AIDS 23, 897–906 (2009).

  18. 18.

    et al. J. Virol. 84, 7161–7173 (2010).

  19. 19.

    Lancet 370, 1665 (2007).

  20. 20.

    & N. Engl. J. Med. 359, 888–890 (2008).

  21. 21.

    , & AIDS 23, 3–8 (2009).

  22. 22.

    et al. Science 300, 2036–2039 (2003).

  23. 23.

    Coordinating Committee of the Global HIV/AIDS Vaccine Enterprise. PLoS Med. 2, e25 (2005).

  24. 24.

    et al. PLoS Med. 4, e348 (2007).

  25. 25.

    et al. PLoS Med. 5, e81 (2008).

  26. 26.

    , & Curr. Opin. HIV AIDS 4, 431–440 (2009).

  27. 27.

    UNAIDS & World Health Organization. Ethical Considerations in Biomedical HIV Prevention Trials: UNAIDS, WHO guidance document. (UNAIDS, Geneva, 2007).

  28. 28.

    UNAIDS & AVAC. Good Participatory Practice: Guidelines for Biomedical HIV Prevention Trials. (UNAIDS, Geneva, 2007).

  29. 29.

    , , & the Working Group convened by the Global HIV Vaccine Enterprise. Preprint at (2010).

  30. 30.

    , & the Working Group convened by the Global HIV Vaccine Enterprise. Preprint at (2010).

  31. 31.

    , , & the Working Group convened by the Global HIV Vaccine Enterprise. Preprint at (2010).

  32. 32.

    , , & the Working Group convened by the Global HIV Vaccine Enterprise. Preprint at (2010).

  33. 33.

    et al. Preprint at (2010).

  34. 34.

    Immunity 29, 835–838 (2008).

  35. 35.

    et al. Communications Handbook for Clinical Trials (Family Health International, Research Triangle Park, NC, 2010).

  36. 36.

    et al. PLoS Genet. 5, e1000791 (2009).

  37. 37.

    et al. J. Infect. Dis. 200, 1194–1201 (2009).

  38. 38.

    & Curr. Opin. HIV AIDS 4, 247–252 (2009).

  39. 39.

    et al. Nat. Immunol. 10, 116–125 (2009).

  40. 40.

    & Nature 461, 908–915 (2009).

  41. 41.

    et al. J. Exp. Med. 205, 3119–3131 (2008).

  42. 42.

    Nat. Rev. Immunol. 9, 741–747 (2009).

  43. 43.

    Committee on Science, Engineering, and Public Policy. Ensuring the Integrity, Accessibility, and Stewardship of Research Data in The Digital Age. (National Academies Press,Washington, DC, 2009).

  44. 44.

    et al. J. Virol. 78, 3140–3144 (2004).

  45. 45.

    HIV Vaccines and Microbicides Resource Tracking Working Group. Advancing the Science in a Time of Fiscal Constraint: Funding for HIV Prevention Technologies in 2009. (2010).

  46. 46.

    & Science 328, 1359–1360 (2010).

Download references

Acknowledgements

The 2010 Scientific Strategic Plan of the Global HIV Vaccine Enterprise was developed through a broad process of consultation. Thanks are given to the co-chairs of the various Enterprise Working Groups (A. Aderem, B. Autran, D. Barouch, L. Corey, R. King, J. Mascola, F. McCutchan, A. McMichael, T. Ndung'u, L. Picker, B. Pulendran, R. Rappuoli and R. Steinman), to Working Group members and to the Enterprise Science Committee for their invaluable insights and recommendations that have informed the development of this document. R. Lackman, R. Wiley and B. Snow provided much appreciated assistance and advice. Special thanks to A. Manrique and Y. Voronin for their invaluable support, input and suggestions at all stages during the process of developing the Plan.

Author information

Affiliations

  1. IAVI, New York, New York, USA.

    • Seth Berkley
  2. MHRP, Rockville, Maryland, USA.

    • Kenneth Bertram
  3. ANRS, Paris, France.

    • Jean-François Delfraissy
    •  & Yves Lévy
  4. European Commission, Brussels, Belgium.

    • Ruxandra Draghia-Akli
    •  & Manuel Romaris
  5. NIH-NIAID, Bethesda, Maryland, USA.

    • Anthony Fauci
    •  & Margaret I Johnston
  6. Enterprise Secretary-Treasurer, New York, New York, USA.

    • Cynthia Hallenbeck
  7. First Lady of Rwanda, Kigali, Rwanda.

    • Madame Jeannette Kagame
  8. Merck Research Laboratories, Rahway, New Jersey, USA.

    • Peter Kim
  9. WHO-UNAIDS, Geneva, Switzerland.

    • Daisy Mafubelu
    •  & Catherine Hankins
  10. University of KwaZulu-Natal, Durban, South Africa.

    • Malegapuru W Makgoba
  11. London School of Hygiene and Tropical Medicine, London, UK.

    • Peter Piot
  12. Wellcome Trust, London, UK.

    • Mark Walport
  13. AVAC: Global Advocacy for HIV Prevention, New York, New York, USA.

    • Mitchell Warren
  14. The Bill & Melinda Gates Foundation, Seattle, Washington, USA.

    • Tadataka Yamada
    •  & José Esparza
  15. Emory Vaccine Center and Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, USA.

    • Rafi Ahmed
  16. Global HIV Vaccine Enterprise, New York, New York, USA

    • Alan Bernstein

Consortia

  1. The Council of the Global HIV Vaccine Enterprise

    Complete lists of authors and affiliations appear at the end of this paper.

  2. Members of the Enterprise

  3. Alternate members

  4. Ex-officio members

Authors

    Competing interests

    The author declare no competing financial interests.

    Corresponding author

    Correspondence to Alan Bernstein.

    About this article

    Publication history

    Published

    DOI

    https://doi.org/10.1038/nm0910-981

    Note: Opinions reflected in this manuscript do not necessarily reflect the official policies of the agencies represented by Council members.

    Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing